Could a Grape-Seed Pill Really Help Humans Live to 150 ages

SHENZHEN — A Chinese biotechnology company has drawn international attention with an experimental pill based on grape-seed compound PCC1, but claims of dramatically extending human lifespan remain unproven.

 

 

 

6

A Pill Built Around “Zombie Cells”

Lonvi Biosciences, a Shenzhen-based longevity company, has developed a supplement centered on procyanidin C1, or PCC1, a compound derived from grape seeds and studied for effects on aging cells.

The company describes PCC1 as a senolytic compound, meaning it is intended to target senescent cells that have stopped dividing but remain active within aging tissues.

These cells, sometimes called “zombie cells,” can release inflammatory molecules known collectively as the senescence-associated secretory phenotype, or SASP, which researchers associate with age-related deterioration.

Lonvi’s product is marketed as a three-day monthly protocol, with the company saying its newer formulation uses phytosomal technology intended to improve absorption of the active compounds.

Where the 150-Year Claim Came From

The dramatic “150 years” claim gained attention after Lonvi’s chief technology officer, Lyu Qinghua, said living to 150 was realistic and could eventually become reality.

That statement was subsequently amplified across international media, turning an experimental longevity project into a viral story about a potential “pill to live to 150.”

However, the 150-year figure is not the result of a completed human clinical trial demonstrating that PCC1 extends human lifespan.

Instead, the scientific foundation comes largely from laboratory and animal research, particularly studies examining PCC1’s effects on senescent cells and aging mice.

What the Mouse Research Found

A 2021 study published in Nature Metabolism reported that PCC1 affected senescent cells and increased healthspan and lifespan in mice under experimental conditions.

Researchers found that PCC1 appeared to suppress inflammatory signaling at lower concentrations while selectively killing senescent cells at higher concentrations through mechanisms involving cellular stress.

Reports surrounding the study have highlighted an approximately 9.4% increase in overall lifespan, while the increase measured from treatment initiation in older mice was substantially larger.

Those figures describe results in laboratory animals and cannot simply be converted into an equivalent human lifespan of 150 years.

A Significant Scientific Caveat

The original Nature Metabolism paper received an Editorial Expression of Concern in February 2026, meaning the journal has formally flagged issues requiring readers’ attention.

That development does not automatically invalidate every finding involving PCC1, but it means the original evidence should be interpreted cautiously while questions surrounding the paper are considered.

Additional research has continued to investigate PCC1, including studies examining its effects on aging-related processes in specific tissues and animal models.

A 2026 study, for example, reported that an oral PCC1 formulation improved several aging-related measures in mice, while also noting limitations involving PCC1’s relatively poor oral bioavailability.

What About Human Evidence?

Lonvi currently cites preliminary human data involving 17 participants between 50 and 86 years old, but the company describes those findings as preliminary and still undergoing peer review.

The company reports reductions in several biological markers after a short three-day supplementation period, including p21, SA-β-gal and selected inflammatory factors.

Those measurements may provide clues about biological mechanisms, but they do not demonstrate that participants will live longer or that PCC1 can extend human lifespan.

Importantly, there is currently no completed human clinical trial demonstrating that PCC1 can increase human lifespan to 150 years.

The Price Behind the Viral Story

Lonvi currently lists its PCC1 Grape Seed Complex at $250, while another version of the company’s PCC1 product has been marketed at approximately $199.

The company presents the products as specialized senolytic supplements rather than established medicines proven to extend human life.

That distinction is important because consumers may interpret dramatic longevity headlines differently from the limited scientific evidence currently available.

Why Scientists Remain Interested

Despite the uncertainty, senolytics remain an active area of aging research because senescent cells appear to contribute to inflammation and dysfunction across multiple biological systems.

Researchers are investigating whether selectively removing or modifying these cells could eventually help prevent or treat certain age-related diseases.

The broader field includes compounds and approaches beyond PCC1, including pharmaceutical senolytics, metabolic interventions and experimental cellular-reprogramming technologies.

Nature Medicine recently emphasized that longevity research still needs stronger clinical evidence, reliable aging biomarkers and rigorous testing before anti-aging interventions can be considered established treatments.

The Bigger Question

The possibility of humans reaching 150 years is not necessarily excluded by every longevity researcher, but the scientific question is very different from proving that a particular pill can achieve it.

Nature has reported that some researchers believe major increases in human longevity could eventually occur, while others remain skeptical about how far lifespan can realistically be extended.

For now, PCC1 represents an experimental approach built around an interesting biological mechanism rather than a proven human life-extension treatment.

The research may produce important findings about cellular aging, but translating results from mice and short-term human biomarkers into decades of additional human life remains a major scientific challenge.

What happens next will depend on controlled human trials, longer-term safety data and evidence showing whether biological changes associated with PCC1 actually translate into better health and longer lives.

For now, the viral claim of a pill capable of helping humans live to 150 should be understood as a company-linked longevity hypothesis, not an established medical result.

Sources: Nature Metabolism, Nature Medicine, Nature, Lonvi Biosciences, India Today and other reporting on PCC1 and longevity research.